Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. / Wave Life Sciences Ltd.

2018 · Co-Development · $2.0B · Complete

Takeda and Wave Life Sciences formed a global strategic collaboration in February 2018 to develop nucleic acid therapies for CNS disorders. Takeda paid $110M upfront, $60M in equity at $54.70/share, and committed at least $60M in research funding over four years. Total deal could reach ~$2B+ across four lead programs (HD, ALS, FTD, SCA3) plus options on multiple preclinical programs targeting Alzheimer's and Parkinson's.

Key facts

• Announced Feb 20, 2018
• Deal value $2.0B
• Deal type Co-Development
• Therapeutic area Huntington's disease, ALS, frontotemporal dementia, spinocerebellar ataxia type 3
• Indications Huntington's disease, ALS, frontotemporal dementia, spinocerebellar ataxia type 3
• Key assets WVE-120101 / WVE-120102 (mutant HTT) and WVE-3972-01 (C9ORF72)
• Mechanism Stereopure antisense oligonucleotides targeting CNS disease-causing genes

← Browse all deals  ·  How we score deals